Iovance Biotherapeutics, Inc. (IOVA) stock
IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3087% above fair value
$7.53−0.02 (-0.26%)
Close on Nov 17, 2026Market cap $3.41BP/E –Yield –
Iovance Biotherapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Iovance Biotherapeutics's enterprise value was $3.37B on Nov 11, 2026, against $651.29M a year earlier. Over the last 5 years it ranged from $214.65M to $6.42B, with a median of $1.27B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $3.37B | +348.0% |
| 2025 | Dec 31, 2025 | $751.51M | -59.5% |
| 2024 | Dec 31, 2024 | $1.86B | +8.0% |
| 2023 | Dec 29, 2023 | $1.72B | +164.8% |
| 2022 | Dec 30, 2022 | $649.43M | -73.1% |
| 2021 | Dec 31, 2021 | $2.42B | -60.3% |
| 2020 | Dec 31, 2020 | $6.08B | +94.2% |
| 2019 | Dec 31, 2019 | $3.13B | +358.5% |
| 2018 | Dec 31, 2018 | $682.96M | +65.7% |
| 2017 | Dec 29, 2017 | $412.24M | +64.1% |
| 2016 | Dec 30, 2016 | $251.24M | -3.0% |
| 2015 | Dec 31, 2015 | $258.93M | +29.2% |
| 2014 | Dec 31, 2014 | $200.33M | +26.7% |
| 2013 | Dec 31, 2013 | $158.14M | +818.1% |
| 2012 | Dec 31, 2012 | $17.22M | -76.6% |
| 2011 | Dec 30, 2011 | $73.51M | – |
See a number that looks wrong?